Literature DB >> 19412190

Therapy: A local approach to Raynaud phenomenon.

Ariane L Herrick1.   

Abstract

The current treatment options for Raynaud phenomenon are often ineffective and can have undesirable adverse effects. Topical, or transdermal, treatments that increase digital blood flow without systemic adverse effects are, therefore, an attractive option. A novel topical nitroglycerin formulation has shown promise in treating Raynaud attacks.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19412190     DOI： 10.1038/nrrheum.2009.64

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  8 in total

Review 1.  Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.

Authors:  A E Thompson; J E Pope
Journal:  Rheumatology (Oxford)       Date:  2004-11-16       Impact factor: 7.580

2.  The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon; studies on blood flow and clinical manifestations.

Authors:  M KLECKNER; E V ALLEN; K G WAKIM
Journal:  Circulation       Date:  1951-05       Impact factor: 29.690

3.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.

Authors:  A E Thompson; B Shea; V Welch; D Fenlon; J E Pope
Journal:  Arthritis Rheum       Date:  2001-08

4.  Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  M E Anderson; T L Moore; S Hollis; M I V Jayson; T A King; A L Herrick
Journal:  Rheumatology (Oxford)       Date:  2002-03       Impact factor: 7.580

5.  Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease.

Authors:  A G Franks
Journal:  Lancet       Date:  1982-01-09       Impact factor: 79.321

6.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Authors:  Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; Maureen D Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara White; James R Seibold; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2002-09

7.  Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.

Authors:  L S Teh; J Manning; T Moore; M P Tully; D O'Reilly; M I Jayson
Journal:  Br J Rheumatol       Date:  1995-07

8.  MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.

Authors:  Lorinda Chung; Lee Shapiro; David Fiorentino; Murray Baron; Joseph Shanahan; Sangeeta Sule; Vivien Hsu; Naomi Rothfield; Virginia Steen; Richard W Martin; Edwin Smith; Maureen Mayes; Robert Simms; Janet Pope; Bashar Kahaleh; M E Csuka; Barry Gruber; David Collier; Nadera Sweiss; Adam Gilbert; Frederick J Dechow; Jeffrey Gregory; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2009-03
  8 in total
  1 in total

Review 1.  Assessing microvascular changes in systemic sclerosis diagnosis and management.

Authors:  Maurizio Cutolo; Alberto Sulli; Vanessa Smith
Journal:  Nat Rev Rheumatol       Date:  2010-08-10       Impact factor: 20.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.